The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View pso content recommended for you

ACR Convergence 2023: Top abstracts in psoriasis and psoriatic arthritis

By Ella Dixon

Nov 1, 2023

To help navigate the exciting content being presented at American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

Psoriasis
2255	Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
1920	A Phase Ib/II randomized, double-blind, placebo-controlled study of novel anti-IL-17A monoclonal antibody JS005 in patients with moderate to severe psoriasis
1418	Efficacy of the oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active PsA: Results from a phase 2 trial
0261	Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results
0443	The potential of an oral TNFα inhibitor with TNFR1 specificity: Results of a phase 1b proof-of-mechanism trial in psoriasis

Psoriatic arthritis
1433	Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies
1422	Long-term safety of risankizumab in patients with psoriatic disease: integrated analysis of psoriasis and psoriatic arthritis clinical trial data
L12	Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis
0485	Sex and treatment-associated outcomes in patients with active psoriatic arthritis treated with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial
0776	Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: 16- and 52-week results from a randomized, double-blind, phase 3 study

ACR Convergence 2023 Abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ACR 2023 Psoriasis Psoriatic arthritis

Subscribe to get the best content delivered to your inbox

ACR Convergence 2023: Top abstracts in psoriasis and psoriatic arthritis

Newsletter

Areas of interest